KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Retained Earnings (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Retained Earnings data on record, last reported at -$447.0 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 23.07% year-over-year to -$447.0 million; the TTM value through Dec 2025 reached -$447.0 million, down 23.07%, while the annual FY2025 figure was -$447.0 million, 23.07% down from the prior year.
  • Retained Earnings reached -$447.0 million in Q4 2025 per AQST's latest filing, down from -$415.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$200.9 million in Q1 2021 and bottomed at -$447.0 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$316.6 million, with a median of -$311.1 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: tumbled 42.83% in 2021, then fell 2.53% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$256.8 million in 2021, then fell by 21.19% to -$311.2 million in 2022, then dropped by 2.53% to -$319.1 million in 2023, then dropped by 13.83% to -$363.2 million in 2024, then fell by 23.07% to -$447.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$447.0 million in Q4 2025, -$415.1 million in Q3 2025, and -$399.7 million in Q2 2025.